盐酸福米诺苯

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 盐酸福米诺苯
• 英文名称: N-[3-chloro-2-[[methyl-(2-morpholin-4-yl-2-oxoethyl)amino]methyl]phenyl]benzamide;hydron;chloride
• 化学式: C21H25Cl2N3O3
• 分子量: 438.3
• InChiKey: ZAOHKACVOFGZOI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.53
• 重原子数：
  29
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  63.1
• 氢给体数：
  2
• 氢受体数：
  5

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• [EN] METAL NANOPARTICLE SURFACE LIGAND REPLACEMENT METHOD<br/>[FR] PROCÉDÉ DE REMPLACEMENT DE LIGAND DE SURFACE DE NANOPARTICULE MÉTALLIQUE
  申请人：UNIV WIEN BODENKULTUR

  公开号：WO2018091666A1

  公开（公告）日：2018-05-24

  The invention relates to a method of producing inorganic nanoparticles with a polar surface, a) providing an inorganic nanoparticle with a coordinated organic ligand to the nanoparticles surface, b) providing a replacement salt comprising a replacement ion and a counterion, c) treating the inorganic nanoparticle with the coordinated organic ligand with the replacement salt in the presence of a chelating agent that complexes the counterion, thereby increasing the replacements ion's reactivity and replacing the organic ligand on the nanoparticle surface by the replacement ion which results in an inorganic nanoparticle with a polar surface; and a kit.

  这项发明涉及一种制备具有极性表面的无机纳米颗粒的方法，a)提供具有配位有机配体的无机纳米颗粒至纳米颗粒表面，b)提供包括替代离子和对离子的替代盐，c)在存在络合剂的情况下，用替代盐处理具有配位有机配体的无机纳米颗粒，络合剂络合对离子，从而增加替代离子的反应性并通过替代离子替换纳米颗粒表面上的有机配体，从而得到具有极性表面的无机纳米颗粒；以及一个试剂盒。
• [EN] PROCESS FOR THE PREPARATION OF A POLYUNSATURATED KETONE COMPOUND<br/>[FR] PROCÉDÉ POUR LA PRÉPARATION D'UN COMPOSÉ POLYINSATURÉ DE CÉTONE
  申请人：AVEXXIN AS

  公开号：WO2015011206A1

  公开（公告）日：2015-01-29

  The invention relates to the manufacture of certain polyunsaturated compounds employing a particular application of the Mitsonobu reaction in the presence of at least one anti-oxidant. We have found a method of making a pharmaceutically-acccptable polyunsaturated ester or thioester compound directly, which can ultimately be converted to the advantageous ketone compounds, in which unwanted oxidation and cis/trans isomerization are substantially reduced or eliminated using particular Mitsonobu chemistry.

  这项发明涉及在至少一种抗氧化剂存在的情况下，利用Mitsonobu反应的特定应用制造某些多不饱和化合物。我们发现了一种直接制造药用可接受的多不饱和酯或硫酯化合物的方法，最终可以转化为有利的酮化合物，其中使用特定的Mitsonobu化学方法大大减少或消除了不需要的氧化和題/反式异构化。
• ETHYNYLINDOLE COMPOUNDS
  申请人：OHMOTO Kazuyuki

  公开号：US20100160647A1

  公开（公告）日：2010-06-24

  As a compound having a potent oral activity and a long-lasting cysLT 1 /cysLT 2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT 1 /cysLT 2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

  作为一种具有强效口服活性和长效cysLT1/cysLT2受体拮抗活性的化合物，具有公式(I)的化合物表现出对cysLT1/cysLT2受体的强效拮抗活性，并且即使口服后也具有长效作用，因此可用作口服药剂预防和/或治疗各种疾病，例如呼吸道疾病（例如哮喘（支气管哮喘等）、慢性阻塞性肺病（COPD）、肺气肿、慢性支气管炎、肺炎（间质性肺炎等）、严重急性呼吸综合征（SARS）、急性呼吸窘迫综合征（ARDS）、呼吸暂停综合征、过敏性鼻炎、鼻窦炎（急性鼻窦炎、慢性鼻窦炎等）、肺纤维化、咳嗽（慢性咳嗽等）等）。
• [EN] SUBSTITUTED BENZIMIDAZOLIUM COMPOUNDS USEFUL IN THE TREATMENT OF RESPIRATORY DISEASES<br/>[FR] COMPOSÉS SUBTITUÉS À BASE DE BENZIMIDAZOLIUM UTILISABLES DANS LE TRAITEMENT DE MALADIES RESPIRATOIRES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2016113167A1

  公开（公告）日：2016-07-21

  The present invention relates to compounds of formula (I), or the tautomers or pharmacologically acceptable acid addition salts thereof, characterized by a topological polar surface area value (TPSA) of at least 145, wherein R1, R2, R3, R4, X, and Z- have one of the meanings as defined in the specification, to the use of compounds of formula (I) as a medicament, to pharmaceutical composition comprising at least one compound of formula (I), as well as to medicament combinations containing one or more compounds of formula (I).

  本发明涉及公式（I）的化合物，或其互变异构体或药理学上可接受的酸盐，其具有至少145的拓扑极性表面积值（TPSA），其中R1、R2、R3、R4、X和Z-具有规范中定义的含义之一，以及将公式（I）的化合物用作药物的用途，包括至少一种公式（I）的化合物的药物组合物，以及含有一种或多种公式（I）的化合物的药物组合物。